The role of the subjective experience in supporting positive effects following psilocybin: a randomized, controlled clinical trial using risperidone in healthy adults
Summary
We are looking for healthy adults to take part in a research study investigating the importance of subjective experience in facilitating positive outcomes induced by psilocybin. The study has 5 visits and takes place in the Cal Wenzel Building at the Foothills Campus of the University of Calgary.
The first visit (Visit 1) will take about 3 hours or less and includes questions about your health and lifestyle, psychiatric and medical history, an ECG exam, and collecting one blood draw and one urine sample. If deemed eligible to participate, the second visit will take 2 hours or less and includes questionnaires assessing mood, personality, well-being, and state and train anxiety, as well as 3 computer tasks assessing cognitive flexibility. The third visit will consist of the medication administration session – you will receive either a high or a low dose of psilocybin, in combination with either the atypical antipsychotic risperidone or placebo. During the session, we will monitor your heart rate using a chest strap monitor, and we will collect blood samples at multiple intervals using an IV catheter. At the end of the session, you will be asked to complete questionnaires asking about your subjective experience. One week later (visit 4), you will complete the first follow-up visit, which will take around 2 hours and will repeat the same measures you completed during visit 2, with the addition of one questionnaire. Three weeks later (visit 5), you will complete the second follow-up visit, which will have the same format as visit 4 and will also take around 2 hours.
The study has been approved by the University of Calgary Conjoint Health Research Ethics Board (REB24-1121)
As a thank you for your time, participants receive gift card compensation for each completed visit:
Total possible compensation: $160 CAD
* Visit 3: $40 CAD each
* Visits 4: $50 CAD
* Visit 5: $70 CAD
Currently Recruiting!
If you are interested in participating, please complete the following brief questionnaire and click Submit at the end: https://forms.office.com/Pages/ResponsePage.aspx?id=7KAJxuOlMUaWhhkigL2RUe5jagp4ZTpImfIOiTbK-RpURTBaVklFQ09ZV0daTklPVjlFTjVGQjFUQi4u
If you meet the eligibility criteria, you will be contacted within 3–5 business days to schedule the first visit.
Eligibility
Eligible ages: 18 to 65
Accepts healthy participants: Yes
Inclusion criteria:
In order to be eligible to participate in this study you must meet all the following criteria:
1. all sexes, gender identities, and ethnicities
2. between 18 and 65 years
3. ability to read/write English
4. willing to refrain from consuming any alcohol or psychoactive drugs within 24 hours of your study visits, with the exception of caffeine and nicotine
5. willing to refrain from consuming psychedelics during trial participation
Exclusion criteria:
You are not eligible to participate in this study if you fulfill any of the following criteria:
1. current psychiatric disorders (e.g. depression or addiction) which will be determined at the first session in a structured interview
2. personal or family history of schizophrenia, bipolar, or psychosis
3. adverse events following previous psychedelic use
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Ana Deutsch Research Coordinator pactlab@ucalgary.ca
Principal investigator:
Thomas Raedler
Clinical trial:
Yes
REB-ID:
REB24-1121
External links